Anzeige
Mehr »
Donnerstag, 25.09.2025 - Börsentäglich über 12.000 News
Geheime Börsenchance: Ist das die bedeutendste Kupferentdeckung Kanadas?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DFK1 | ISIN: IL0011809592 | Ticker-Symbol: H1Z
Frankfurt
24.09.25 | 08:02
1,030 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEUROSENSE THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
NEUROSENSE THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur NEUROSENSE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:24NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln
10.09.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer2
10.09.NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons94Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass., Sept. 10...
► Artikel lesen
08.09.RECIPHARM AB: Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials2
04.09.NeuroSense Therapeutics announces $500,000 private placement1
02.09.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer3
20.08.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
15.08.NeuroSense Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans1
01.08.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer3
10.07.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
26.06.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
12.05.This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday19
12.05.Boral Capital starts NeuroSense stock with Buy, $14 target12
07.05.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer-
24.04.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer2
24.04.NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update164Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about...
► Artikel lesen
09.04.NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment283New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/...
► Artikel lesen
08.04.NeuroSense Therapeutics GAAP EPS of -$0.543
07.04.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
07.04.NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates160Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1